Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vanda Pharmaceuticals Inc (VNDA) Fair Value & Analysis

Healthcare · US · Market cap $355M

Price$5.90
Fair Value$3.08
Upside-47.8%
Quality95/100
Evidence: Low Range $2.04 – $3.86

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Vanda Pharmaceuticals Inc (VNDA) currently trades at $5.90, while our model-based Fair Value estimate is $3.08 — implying the stock looks roughly 47.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (pon…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Vanda Pharmaceuticals Inc (VNDA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.08 versus a price of $5.90 — about −48% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VNDA?
Our 21-model fair value for Vanda Pharmaceuticals Inc is $3.08 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.90.
What is the quality score of VNDA?
Vanda Pharmaceuticals Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.